***Supplementary Table S1: Description of the sample***

|  |  |
| --- | --- |
| Characteristics | N (%) or mean (SD) |
| Sex, n (%) Female Male | 1797 (62.2)1094 (37.8) |
| Mean age (SD) | 40.5 (12.9) |
| High school graduation, n (%) | 1794 (71.1) |
| Bipolar subtype, n (%) Bipolar I Bipolar II Bipolar NOS | 1327 (45.9)1260 (43.6)304 (10.5) |
| Age at onset of bipolar disorders, mean (SD), years | 23.7 (9.4) |
| Duration of the disease, mean (SD), years | 16.7 (11.1) |
| Number of lifetime episode, mean (SD) | 8.8 (9.3) |
| Depressive symptoms, mean (SD) | 10.2 (9.0) |
| Manic symptoms, mean (SD) | 2.4 (3.7) |
| Rapid cycling, n (%) | 422 (16.9) |
| Lifetime psychiatric comorbidities, n (%) Anxiety disorders Substance use disorders | 1186 (44.5)977 (36.3) |
| Sleep disorders, mean (SD) | 7.1 (3.8) |
| Current smokers, n (%) | 1271 (46.0) |
| Body Mass Index (kg/m2), mean (SD) | 25.7 (5.3) |
| Current medication, n (%) Antidepressants Second Generation antipsychotics Mood stabilizers (anticonvulsants) Lithium Anxiolytics | 853 (39.4)835 (38.6)1109 (51.2)727 (33.6)630 (29.1) |
| Number of psychotropic medications, mean (SD) | 2.2 (1.2) |

***Supplementary Table S2: Frequency of somatic comorbidities***

|  |  |  |
| --- | --- | --- |
| **Type of disorders** | **Diseases** | **N (%)** |
| Neurological disorders | Epilepsy | 53 (1.8) |
| Headache/migraine | 600 (20.8) |
| Multiple sclerosis | 5 (0.17) |
| Meningitis | 44 (1.5) |
| Stroke | 25 (0.87) |
| Cardio-vascular disorders | Hypertension | 202 (7.0) |
| Coronary disease | 11 (0.38) |
| Myocardial infarction | 14 (0.49) |
| Heart rhythm disorders | 100 (3.46) |
| Metabolic disorders | Diabetes | 80 (2.77) |
| Dysthyroidia | 333 (11.5) |
| Dyslipidemia | 430 (14.9) |
| Skin disorders | Eczema | 341 (11.8) |
| Psoriasis | 235 (8.1) |
| Drug-induced toxidermia | 222 (7.7) |
| Acne | 376 (13.0) |
| Urinary tract disorders | Nephropathy | 44 (1.50) |
| Acute urine retention | 41 (1.44) |
| Liver and digestive disorders | Cirrhosis | 3 (0.10) |
| Peptic ulcer | 90 (3.11) |
| Drug-induced hepatitis | 44 (1.54) |
| Bowel disease | 26 (0.91) |
| Allergy and auto-immune disorders | Asthma | 251 (8.7) |
| Other allergy | 538 (18.6) |
| Lupus erythematosus | 3 (0.10) |
| Rheumatoid arthritis | 5 (0.17) |
| Infectious disorders | HIV infection | 8 (0.29) |
| Chronic viral hepatitis | 45 (1.66) |
| Cancer |  | 87 (3.0) |

***Supplementary table S3: Prevalence and age at onset (AAO) of the 15 most frequent somatic comorbidities (ordered from lowest to highest median AAO) (n=2891), ordered from the lowest to the highest median age at onset***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **N present** | **Cumulative prevalence (%)** | **AAO (median)** | **IQR for AAO** |
| Asthma | 251 | 8.7% | 10 | 5-22 |
| Acne | 376 | 13.0% | 15 | 13-20 |
| Eczema | 341 | 11.8% | 17 | 7-28 |
| Allergy | 538 | 18.6% | 17 | 8-28 |
| Headache/migraine | 600 | 20.8% | 19 | 13-29 |
| **Median AAO of bipolar disorders= 21 years (17-28)** |
| Psoriasis | 235 | 8.1% | 22 | 15-36 |
| Epilepsy | 53 | 1.8% | 23 | 7-33 |
| Drug-induced toxidermia | 222 | 7.7% | 27 | 18-37 |
| Peptic ulcer | 90 | 3.1% | 30 | 23-40 |
| Heart rhythm disorders | 100 | 3.5% | 32 | 20-49 |
| Thyroid diseases | 333 | 11.5% | 39 | 29-47 |
| Dyslipidemia | 430 | 14.9% | 41 | 31-49 |
| Diabetes | 80 | 2.8% | 41 | 31-51 |
| Hypertension | 202 | 7.0% | 44 | 33-53 |
| Cancer | 87 | 3.0% | 46 | 34-53 |

AAO: Age At Onset, IQR: InterQuartile.

**Supplementary table S4: Prevalence of medical comorbidities by tertiles of CTQ total score**

|  |  |  |
| --- | --- | --- |
|  | **Childhood maltreatment (n=2891)** |  |
|  | **1er tertile (<34)****N=906** | **2e tertile** **(34-45)****N=1027** | **3e tertile (>45)****N=958** | **P value** |
| Asthma | 65 (7.2) | 104 (10.2) | 82(8.6) | 0.07 |
| Acne | 114 (12.6) | 127(12.4) | 135 (14.1) | 0.47 |
| Eczema | 89 (9.8) | 125 (12.2) | 127 (13.3) | 0.06 |
| Allergy | 171 (18.9) | 211 (20.6) | 156 (16.3) | 0.05 |
| **Migraine/Headache** | **150 (16.6)** | **201 (19.6)** | **249 (26.0)** | **<0.0001** |
| Epilepsy | 14 (1.6) | 26 (2.6) | 13 (1.4) | 0.11 |
| Psoriasis | 63 (6.9) | 79 (7.7) | 93 (9.7) | 0.08 |
| **Drug eruption** | **66 (7.3)** | **66 (6.3)**  | **90 (9.4)** | **0.04** |
| **Duodenal ulcer** | **16 (1.8)** | **32 (3.1)** | **42 (4.4)** | **0.005** |
| Heart diseases | 31 (3.4) | 26 (2.7) | 43 (4.2) | 0.20 |
| **Thyroid diseases** | **85 (9.4)** | **104 (10.1)** | **144 (15.0)** | **0.0002** |
| Dyslipidemia | 116 (12.8) | 158 (15.4) | 156 (16.3) | 0.10 |
| Diabetes | 23 (2.5) | 26 (2.5) | 31 (3.2) | 0.56 |
| Hypertension | 57 (6.3) | 77 (7.5) | 68 (7.1) | 0.58 |
| Cancer | 27 (3.0) | 27 (2.6) | 33 (3.4) | 0.57 |

**Supplementary Table S5: Median age at onset of medical comorbidities according to tertiles of CTQ total score**

|  |  |
| --- | --- |
|  | **Childhood maltreatment** |
|  | **1er tertile** **(<34)****N=906** | **2e tertile** **(34-45)****N=1027** | **3e tertile** **(>45)****N=958** | **P value** |
| Asthma | 9.4 (4.9-21.0) | 9.7 (5.2-17.1) | 14.0 (5.4-25.5) | 0.25 |
| Acne | 15.1 (13.1-19.6) | 15.8 (13.5-19.2) | 14.7 (12.6-22.8) | 0.47 |
| Eczema | 16.1 (6.9-26.5) | 17.3 (6.4-28.4) | 18.3 (8.5-27.3) | 0.85 |
| Allergy | 16.0 (7.3-27.2) | 16.5 (7.4-28.2) | 18.5 (9.5-30.2) | 0.85 |
| Headache | 18.2 (13.4-29.8) | 18.8 (13.5-28.2) | 18.8 (13.7-27.4) | 0.92 |
| Epilepsy | 25.9 (9.8-36.8) | 22.6 (6.9-31.2) | 20.2 (9.7-25.7) | 0.83 |
| Psoriasis | 25.3 (15.5-39.8) | 20.6 (14.7-30.4) | 21.3 (14.9-33.2) | 0.27 |
| Drug eruption | 28.4 (16.6-34.7) | 26.7 (19.3-38.1) | 26.9 (17.9-39.2) | 0.86 |
| Duodenal ulcer | 31.8 (21.0-38.9) | 33.5 (24.4-46.0) | 30.3 (23.3-37.2) | 0.38 |
| Heart diseases | 29.6 (23.6-46.7) | 46.6 (21.7-52.7) | 27.3 (18.5-47.8) | 0.35 |
| Thyroid diseases | 35.6 (26.7-48.6) | 39.2 (28.8-46.9) | 39.0 (29.8-46.8) | 0.92 |
| Dyslipidemia | 36.9 (27.8-48.7) | 40.3 (30.3-49.9) | 43.4 (33.7-48.6) | 0.21 |
| Diabetes | 44.7 (37.5-53.8) | 38.0 (31.7-50.8) | 41.5 (24.6-48.2) | 0.56 |
| Hypertension | 44.9 (35.6-53.8) | 47.8 (36.6-55.7) | 41.7 (28.7-51.0) | 0.09 |
| Cancer | 43.2 (34.5-53.9) | 46.7 (35.6-55.2) | 45.2 (30.7-49.7) | 0.63 |